Dopamine D1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? 1990

J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
Department of Pharmacology, University of Turku, Finland.

The first selective D1 dopamine receptor antagonist, SCH23390, has been reported to be active in preclinical tests that predict antipsychotic activity in schizophrenic patients. This is particularly exciting because it has been claimed that this compound is 'atypical', in that it has a reduced propensity to induce extrapyramidal side-effects. However, in considering the evidence from preclinical screening tests for antipsychotic activity and extrapyramidal side-effects of potential neuroleptic drugs, Jarmo Hietala and colleagues conclude that the majority of available data is not compatible with the postulated atypical profile of SCH23390.

UI MeSH Term Description Entries
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001480 Basal Ganglia Diseases Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. Extrapyramidal Disorders,Basal Ganglia Disorders,Lenticulostriate Disorders,Basal Ganglia Disease,Basal Ganglia Disorder,Extrapyramidal Disorder,Lenticulostriate Disorder
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
September 1991, European journal of pharmacology,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
July 2005, Synapse (New York, N.Y.),
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
January 1999, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
February 2004, Journal of clinical psychopharmacology,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
September 2013, Behavioural brain research,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
January 1999, European archives of psychiatry and clinical neuroscience,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
August 2010, Nordic journal of psychiatry,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
May 1992, The British journal of psychiatry. Supplement,
J Hietala, and J Lappalainen, and M Koulu, and E Syvälahti
January 2000, Therapie,
Copied contents to your clipboard!